文献速递消化道肿瘤与早癌消化内镜

林奇综合征结直肠癌监测策略的基因特异性差异

Gene-Specific Variation in Colorectal Cancer Surveillance Strategies for Lynch Syndrome.
PubMed 文献 · Gastroenterology · 2021-04-09

该研究构建马尔可夫模拟模型,分析MLH1、MSH2、MSH6和PMS2不同错配修复基因变异携带者结肠镜起始年龄和监测间隔对结直肠癌发病、死亡、质量调整生命年和成本的影响。结果显示MLH1和MSH2变异者最优策略为25岁起始、1-2年间隔;MSH6和PMS2变异者分别35岁和40岁起始、3年间隔具有成本效果。

要点

  • MLH1/MSH2变异者:25岁起结肠镜监测,间隔1-2年。
  • MSH6变异者:35岁起监测、3年间隔具成本效果。
  • PMS2变异者:40岁起监测、3年间隔具成本效果。

核心结论

  • 基于MMR基因变异的模拟模型支持对MLH1或MSH2变异者进行强化监测,而MSH6或PMS2变异者可考虑更晚起始和更长间隔。

研究设计与样本

  • 研究使用已发表文献构建马尔可夫模拟模型,模拟林奇综合征携带者的临床试验,变化结肠镜起始年龄(25-40岁,5年递增)和监测间隔(1-5年)。
  • 模型针对MLH1、MSH2、MSH6和PMS2每种错配修复基因变异分别评估最优策略,最优策略定义为质量调整生命年最高且增量成本效果比低于100,000美元支付意愿阈值的策略。

主要发现

  • 对于MLH1和MSH2基因致病变异患者,最优监测为25岁开始结肠镜、间隔1-2年。
  • 对于MSH6基因致病变异患者,35岁开始结肠镜、间隔3年具有成本效果。
  • 对于PMS2基因致病变异患者,40岁开始结肠镜、间隔3年具有成本效果。

关键数值与推荐

  • 最优策略定义为质量调整生命年最高且增量成本效果比低于100,000美元支付意愿阈值。
  • MLH1和MSH2变异者:结肠镜起始年龄25岁,监测间隔1-2年。
  • MSH6变异者:结肠镜起始年龄35岁,监测间隔3年。
  • PMS2变异者:结肠镜起始年龄40岁,监测间隔3年。

临床怎么用

  • 临床可依据林奇综合征相关MMR基因变异类型个体化制定结直肠癌监测起始年龄和间隔。
  • 对MLH1或MSH2变异者维持25岁起始、1-2年间隔的强化监测。
  • 对MSH6或PMS2变异者可考虑分别延迟至35岁和40岁起始监测,并采用3年间隔。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Lynch syndrome is associated with pathogenic variants in 4 mismatch repair (MMR) genes that increase lifetime risk of colorectal cancer. Guidelines recommend intensive colorectal cancer surveillance with colonoscopy every 1-2 years starting at age 25 years for all carriers of Lynch syndrome-associated variants, regardless of gene product. We constructed a simulation model to analyze the effects of different ages of colonoscopy initiation and surveillance intervals for each MMR gene (MLH1, MSH2, MSH6, and PMS2) on colorectal cancer incidence and mortality, quality-adjusted life-years, and cost. METHODS: Using published literature, we developed a Markov simulation model of Lynch syndrome progression for patients with each MMR variant. The model simulated clinical trials of Lynch syndrome carriers, varying age of colonoscopy initiation (5-year increments from 25-40 years), and surveillance intervals (1-5 years). We assessed the optimal strategy for each gene, defined as the strategy with the highest quality-adjusted life-years and incremental cost-effectiveness ratio below a $100,000 willingness-to-pay threshold. RESULTS: Optimal surveillance for patients with pathogenic variants in the MLH1 and MSH2 genes was colonoscopy starting at age 25 years, with 1- to 2-year surveillance intervals. Initiating colonoscopy at age 35 and 40 years, with 3-year intervals, was cost-effective for patients with pathogenic variants in MSH6 or PMS2, respectively. CONCLUSIONS: We developed a simulation model to select optimal surveillance starting ages and intervals for patients with Lynch syndrome based on MMR variant. The model supports recommendations for intensive surveillance of patients with Lynch syndrome-associated variants in MLH1 or MSH2. However, for patients with Lynch syndrome-associated variants of MSH6 or PMS2, later initiation of surveillance at 35 and 40 years, respectively, and at 3-year intervals, can be considered.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Kastrinos F, Ingram MA, Silver ER, et al. Gene-Specific Variation in Colorectal Cancer Surveillance Strategies for Lynch Syndrome. Gastroenterology. 2021. PMID: 33839100. doi:10.1053/j.gastro.2021.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。